Dynamic Advisor Solutions LLC decreased its holdings in Danaher Co. (NYSE:DHR – Free Report) by 4.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,375 shares of the conglomerate’s stock after selling 327 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Danaher were worth $2,050,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Blue Zone Wealth Advisors LLC grew its position in Danaher by 7.0% during the 3rd quarter. Blue Zone Wealth Advisors LLC now owns 15,893 shares of the conglomerate’s stock worth $4,419,000 after purchasing an additional 1,044 shares during the last quarter. Axiom Advisory LLC grew its holdings in shares of Danaher by 3.3% during the third quarter. Axiom Advisory LLC now owns 19,264 shares of the conglomerate’s stock valued at $5,098,000 after buying an additional 621 shares during the last quarter. Eastover Investment Advisors LLC increased its position in shares of Danaher by 14.5% in the 3rd quarter. Eastover Investment Advisors LLC now owns 6,246 shares of the conglomerate’s stock valued at $1,737,000 after acquiring an additional 791 shares during the period. Callan Family Office LLC raised its stake in Danaher by 13.6% in the 3rd quarter. Callan Family Office LLC now owns 1,823 shares of the conglomerate’s stock worth $507,000 after acquiring an additional 218 shares during the last quarter. Finally, Aprio Wealth Management LLC lifted its position in Danaher by 37.4% during the 3rd quarter. Aprio Wealth Management LLC now owns 1,787 shares of the conglomerate’s stock worth $497,000 after acquiring an additional 486 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Insider Activity
In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $5,566,486.80. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock worth $11,042,433 over the last three months. Insiders own 11.10% of the company’s stock.
Danaher Price Performance
Danaher (NYSE:DHR – Get Free Report) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.05 earnings per share. As a group, equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.40%. The ex-dividend date is Friday, September 27th. Danaher’s payout ratio is 18.31%.
Wall Street Analysts Forecast Growth
Several research analysts have recently issued reports on the company. Bank of America raised their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Wells Fargo & Company initiated coverage on shares of Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Finally, Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.
View Our Latest Stock Report on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Momentum Trades for October With Ample Upside Ahead
- What Are Dividend Contenders? Investing in Dividend Contenders
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
- How to Evaluate a Stock Before Buying
- 2 Reasons to Jump on Apple Stock Now and 1 Reason to Think Twice
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.